Nimble Science develops the SIMBA™ ingestible capsule and an end-to-end GI intelligence platform to collect multi-omic, endoscopy-quality samples from the small intestine non‑invasively. The SIMBA capsule is single‑use, clinically validated to obtain uncontaminated samples from deep regions of the small intestine, and is deployed in industry‑partnered studies worldwide across multiple disease indications. Nimble positions its platform to serve pharmaceutical, diagnostics, and consumer health R&D by providing small‑intestine data that today is largely inaccessible without endoscopy. The company plans to commercialize the SIMBA system and accelerate new product innovation and multi‑omic GI mapping enabled by the recent capital injection. Nimble highlights ease of administration and actionable health data as differentiators versus competing solutions. The company is headquartered in Calgary, Canada.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2024